Analysts Set Prime Medicine, Inc. (NYSE:PRME) Price Target at $7.21

Prime Medicine, Inc. (NYSE:PRME) has received an average rating of “Moderate Buy” from the seven analysts that are presently covering the stock, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $7.2083.

PRME has been the topic of several recent research reports. Wedbush reaffirmed an “outperform” rating and set a $8.00 price objective on shares of Prime Medicine in a report on Monday, November 10th. Lifesci Capital assumed coverage on shares of Prime Medicine in a report on Tuesday, December 23rd. They issued an “outperform” rating and a $6.00 target price for the company. Chardan Capital reduced their price target on shares of Prime Medicine from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Monday, November 10th. Finally, Citigroup decreased their price target on shares of Prime Medicine from $5.00 to $4.25 and set a “neutral” rating on the stock in a research note on Tuesday, November 11th.

Prime Medicine Trading Up 2.0%

Shares of Prime Medicine stock opened at $4.01 on Friday. The firm has a market cap of $724.01 million, a PE ratio of -1.96 and a beta of 2.56. The stock has a 50 day moving average of $3.83 and a 200 day moving average of $4.19. Prime Medicine has a 12 month low of $1.11 and a 12 month high of $6.94.

Trending Headlines about Prime Medicine

Here are the key news stories impacting Prime Medicine this week:

• Positive Sentiment: HC Wainwright raised and tightened EPS forecasts across multiple quarters and years (Q1–Q4 2026 and FY2026–FY2030), cutting projected losses (e.g., FY2026 from ($1.39) to ($1.18) and improvements in FY2027–FY2029). That reduces near-term downside risk from operating losses and signals improving model expectations from a sell-side analyst. MarketBeat — HC Wainwright Estimates
• Positive Sentiment: Lifesci Capital published multiple quarterly and FY2026 estimates with a consistent “Outperform” rating and $6.00 price target, forecasting materially smaller losses for FY2026 (about ($0.90) vs. consensus deeper losses). A high target and repeated positive coverage can support demand for the shares. MarketBeat — Lifesci Capital Note
• Positive Sentiment: Analyst-aggregation coverage shows a favorable consensus (reported as an average “Moderate Buy”), reinforcing the bullish narrative from individual shops and likely contributing to buying interest. American Banking News — Analyst Rating

Institutional Trading of Prime Medicine

Hedge funds have recently made changes to their positions in the business. Creative Planning bought a new position in shares of Prime Medicine in the 2nd quarter valued at about $25,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Prime Medicine during the fourth quarter worth approximately $31,000. Caitong International Asset Management Co. Ltd bought a new stake in Prime Medicine during the fourth quarter worth approximately $33,000. Glen Eagle Advisors LLC purchased a new stake in Prime Medicine during the fourth quarter valued at approximately $35,000. Finally, Savant Capital LLC bought a new stake in shares of Prime Medicine in the 2nd quarter valued at approximately $37,000. 70.37% of the stock is currently owned by hedge funds and other institutional investors.

Prime Medicine Company Profile

Prime Medicine, Inc (NYSE: PRME) is a clinical-stage genetic medicines company focused on harnessing the potential of prime editing, an advanced CRISPR-derived gene editing technology. By refining the tools required for precise correction of disease-causing mutations, Prime Medicine aims to develop single-dose treatments that address underlying genetic drivers of disease. The company applies its proprietary engineering and delivery platforms to optimize on-target efficiency and minimize off-target effects, positioning itself at the forefront of next-generation gene editing therapeutics.

Prime Medicine’s research and development efforts span multiple therapeutic areas, including rare genetic disorders, immuno-oncology, and autoimmune diseases.